title: [The use of ranitidine in antineoplastic polychemotherapy].
abstract: The Author analyzes the ranitidine's role in course of antiblastic treatments. The drug, administrated the night orally at the dose of 300 mgr/pro die, improves the tolerance of antineoplastic drugs and determines less incidence of gastric injuries in oncologic patients.
authors.affiliation: Presidio Ospedaliero di Torrita di Siena, U.S.L. 31, Valdichiana.
authors.forename: A
authors.initials: A
authors.lastname: D'Agata
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000139:chemically induced / Q000517:prevention & control*; D011899:Ranitidine / Q000627:therapeutic use*
chemical_list: D011899:Ranitidine
vernacular_title: Considerazioni sull'impiego della ranitidina in corso di polichemioterapia antineoplastica.